Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANB-033 (Primary)
Indications Coeliac disease; Inflammation
Focus First in man; Therapeutic Use
Sponsors AnaptysBio

Most Recent Events

27 Feb 2025 According to an AnaptysBio media release, enrollment in healthy volunteers is ongoing for the Phase 1a trial for ANB033, phase Ib indication to be disclosed at a 2025 R&D event.
05 Nov 2024 Status changed from planning to recruiting, according to an AnaptysBio media release.
01 Jul 2024 According to an AnaptysBio media release, an IND application was submitted to the FDA and initiation of this trial expected in Q4 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com